Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What’s New in Polymyalgia Rheumatica?

Jason Liebowitz, MD, FACR  |  July 31, 2024

EULAR 2024 (VIENNA)—What’s new in polymyalgia rheumatica (PMR)? That’s the question Frank Buttgereit, MD, senior consultant and deputy head of the Department of Rheumatology and Clinical Immunology, University Medicine, Berlin, set out to answer at EULAR 2024. Harry Spiera, MD, is credited with describing the first American case series of PMR in the 1970s.1 Since then, we have come to recognize PMR as the most common inflammatory disease in people aged 50 and older.2 In this WIN session, Dr. Buttgereit summarized the latest advances in the diagnosis and treatment of PMR.

Assessing Patients

When screening a patient for PMR, Dr. Buttgereit said rheumatologists should also screen for giant cell arteritis (GCA), a frequently overlapping condition whose co-occurrence has implications for patient management. Subclinical GCA in PMR—based on imaging or biopsy—has a pooled prevalence of about 23%, yet the clinical implications of these findings are unclear.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a study conducted by De Miguel et al., 150 patients with PMR and without clinical symptoms of GCA were stratified into two groups: 1) those with isolated PMR and 2) those with subclinical GCA, based on ultrasound imaging. These groups were followed for two years. The study found patients with PMR and subclinical GCA have a fourfold higher rate of relapse than patients with isolated PMR. Additionally, they found a lower starting dose and rapid taper of glucocorticoids in the first three months of treatment increases the risk of relapse in these patients.4

These findings raise the question: Should all patients with PMR have a vascular ultrasound assessment? Dr. Buttgereit believes that such an evaluation should be considered at the time of diagnosis, particularly if clinician sonographers are accessible.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment

Dr. Buttgereit noted that the 2015 Recommendations for the Management of PMR, jointly published by EULAR and the ACR, remains a helpful guideline for practicing rheumatologists.6 This guideline recommends clinicians begin treatment with prednisone in a dose ranging from 12.5–25 mg daily. For patients with a high risk or relapse and low risk of adverse events, the dose can be up to 30 mg of prednisone daily. Conversely, doses as low as 7.5 mg of prednisone daily can be prescribed for patients with comorbidities (i.e., diabetes, osteoporosis or glaucoma).5,6

The initial tapering of glucocorticoids should allow the patient to reach a dose of 10 mg of prednisone daily four to eight weeks after therapy is initiated. Subsequent tapering should be in increments of 1 mg every four weeks.5,6

If the patient experiences a relapse, the prednisone dose can be increased to the pre-relapse level and then decreased gradually over four to eight weeks to the dose at which relapse occurred. Dr. Buttgereit noted that, within the context of these recommendations, it’s important for physicians and patients to participate in shared decision making and routinely discuss the goals of care, which most commonly focus on maximizing health-related quality of life.5,6

Next, Dr. Buttgereit discussed recent clinical trials demonstrating the effectiveness of interleukin (IL) 6 receptor inhibition in the treatment of PMR. These studies include the PMR-SPARE trial of tocilizumab, the SEMAPHORE trial of tocilizumab and the SAPHYR trial of sarilumab.7–9 Although the PMR-SPARE and SEMAPOHORE trials demonstrated positive results for tocilizumab, the SAPHYR trial may be more familiar to rheumatologists in the U.S. because its findings influenced the 2023 U.S. Food & Drug Administration’s approval of sarilumab for the treatment of patients with PMR for whom glucocorticoids have proved inadequate or who cannot tolerate glucocorticoid tapering.10

The SAPHYR trial enrolled 118 patients with PMR, all of whom had:9 1) at least one episode of disease flare during glucocorticoid tapering (at a dose of ≥7.5 mg of prednisone per day) within 12 weeks of screening, and 2) a history of at least eight weeks of glucocorticoid treatment. the investigators randomly assigned patients to receive 200 mg of sarilumab twice per month over 52 weeks plus a 14-week prednisone taper or placebo plus a 52-week prednisone taper. The primary outcome at 52 weeks was sustained remission, defined as the absence of PMR signs/symptoms by week 12, sustained C-reactive protein (CRP) normalization, absence of disease flare and adherence to the prednisone taper from weeks 12 through 52. At week 52, sustained remission occurred in 28% of participants in the sarilumab group and in 10% in the placebo group; this significant difference held true even when ESR and CRP were removed from the analysis. The cumulative glucocorticoid dose at week 52 was lower in the sarilumab group than in the placebo group (777 mg vs. 2,044 mg, respectively). Fewer disease flares occurred after clinical remission at week 12 in the sarilumab group than in the placebo group (24% vs. 57%, respectively). Finally, patients treated with sarilumab had lower glucocorticoid toxicity index scores during 52 weeks (52.32 vs. 57.22) and larger mean improvement in disease activity score from baseline to week 52 (−15.57 vs. −10.27) than those receiving placebo.

Dr. Buttgereit also highlighted several studies evaluating the effectiveness and safety of tofacitinib and rituximab for treating patients with PMR.

In the EAST PMR study, researchers randomized patients to receive either tofacitinib or glucocorticoids for 24 weeks. The study showed no difference in the primary end point—defined as the proportion of patients with PMR-AS score ≤10 at weeks 12 and 24—between the two groups.11

In 2023, Bolhuis et al. published a follow up to the BRIDGE-PMR study, a randomized controlled trial of rituximab for the treatment of PMR. BRIDGE-PMR was a proof-of-concept clinical trial that suggested B cell depletion with rituximab may have glucocorticoid-sparing effects in patients with PMR. The researchers assessed the rates of glucocorticoid-free remission up to one year after infusion of rituximab in an extension of the BRIDGE-PMR trial. They found the proportion of patients in remission remained stable at one year after infusion and a glucocorticoid-sparing effect was demonstrated.12


Jason Liebowitz, MD, is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, New York.

References

  1. Ullman K. Dr. Harry Spiera retires after 60 years in rheumatology. The Rheumatologist. 28 Sep 2023.
  2. Lundberg IE, Sharma A, Turesson C, et al. An update on polymyalgia rheumatica. J Intern Med. 2022 Nov;292(5):717–732.
  3. Hemmig AK, Gozzoli D, Werlen L, et al. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. Semin Arthritis Rheum. 2022 Aug;55:152017.
  4. De Miguel E, Karalilova R, Macchioni P, et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann Rheum Dis. 2024 Feb 15;83(3):335–341.
  5. Dejaco C, Singh PY, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015 Oct;67(10):2569–2580.
  6. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015 Oct;74(10):1799–1807.
  7. Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): A phase 2/3 randomised controlled trial. Ann Rheum Dis. 2022 Jun;81(6):838–844.
  8. Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: A randomized clinical trial. JAMA. 2022 Sep 20;328(11):1053–1062.
  9. Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023 Oct 5;389(14):1263–1272.
  10. Kaufman, MB. FDA approves sarilumab for the treatment of adults with glucocorticoid-resistant PMR. The Rheumatologist. 2023 Mar 14.
  11. Ma X, Yang F, Wu J, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med. 2023 Jun 29;20(6):e1004249.
  12. Bolhuis TE, Marsman DE, den Broeder AA, et al. 1-year results of treatment with rituximab in polymyalgia rheumatica: An extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol. 2023 Apr;5(4):e208–e214.

Page: 1 2 3 4 | Multi-Page
Share: 

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPain Syndromes Tagged with:EULAR 2024GCAgiant cell arteritis (GCA)PMRPolymyalgia Rheumatica

Related Articles

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    New Findings for Polymyalgia Rheumatica & Osteoarthritis

    December 1, 2022

    The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

    How to Treat Refractory Polymyalgia Rheumatica

    January 25, 2024

    Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences